The Board
Professor Ian Chi-Kei WONG, Founder and Chairman
Professor Wong is the Founder and Chairman of ADAMS. He is also the Professor of Department of Pharmacology & Pharmacy and holder of the Lo Shiu Kwan Kan Po Ling Professorship in Pharmacy. He is also the Co-Director of the Centre for Safe Medication Practice and Research. His brief profile can be found at Lancet Psychiatry. He specializes in big data research on medication safety and optimization, particularly for cardiovascular, neurological, and psychological conditions. He has held leadership roles at UCL and HKU, founding key research centres and academic programmes. With over 500 peer-reviewed publications, he ranks among the top 1% of cited scholars globally. He has advised health authorities and the WHO, received numerous fellowships and awards, and led COVID-19 vaccine safety monitoring in Hong Kong. He also serves as an expert witness on medication safety and was Vice-President of the International Society of Pharmacovigilance.
Professor Celine Sze Ling CHUI, Founder and Chief Executive Officer (CEO)
Professor Chui is the Founder and CEO of ADAMS. She is the Assistant Professor at School of Nursing, University of Hong Kong, is a visiting scholar at St George’s University of London and former academic scholar at LSHTM. Recognized among the world’s top 2% most cited scientists, she has received multiple awards and published over 150 articles in leading journals. Her research focuses on real-world evidence to improve population health. She leads several competitive grants and co-chairs NeuroGEN. As a principal investigator of the CARE Programme, she monitors COVID-19 vaccine safety. She also developed P-CARDIAC, an AI tool for cardiovascular risk prediction, now undergoing implementation to enhance patient outcomes.
Professor Ruibang Laurent LUO, Director and Chief AI Development Officer
Dr. Ruibang Luo is the Director and Chief AI Development Officer of ADAMS. He is also the Associate Professor of Computer Science at the University of Hong Kong, specializing in bioinformatics algorithms and clinical informatics. He completed his Ph.D. with Dr. Tak-Wah Lam (HKU) and postdoctoral training at Johns Hopkins University. Luo has published over 80 papers, with ten cited over 1,000 times. Recognized as a Top 1% Scholar by Clarivate since 2019, he was named a Top 10 Innovator Under 35 Asia Pacific (MIT Technology Review, 2019) and 30 Under 30 Asia in Healthcare and Science (Forbes, 2017). Baidu Research also selected him among the Top 150 Chinese AI Scholars.
Research and Development Team
Dr. Yekai ZHOU, AI Scientific Lead
Dr. Xinning TONG, Principal Epidemiologist & Data Analyst
Dr. Xinning TONG, Principal Epidemiologist & Data Analyst
Dr. Yekai Zhou holds a Ph.D. in Computer Science from the University of Hong Kong. Dr. Zhou specializes in developing and deploying advanced AI methodologies—including reinforcement learning and large language models—to address real-world clinical challenges. His work focuses on areas such as disease risk prediction, treatment optimizatio
Dr. Yekai Zhou holds a Ph.D. in Computer Science from the University of Hong Kong. Dr. Zhou specializes in developing and deploying advanced AI methodologies—including reinforcement learning and large language models—to address real-world clinical challenges. His work focuses on areas such as disease risk prediction, treatment optimization, and the creation of intelligent medical chatbots and virtual research agents. Dr. Zhou's research has been featured in leading scientific journals, including npj Digital Health and the European Heart Journal – Digital Health, and has received media coverage for its impact on digital health innovation.
Dr. Xinning TONG, Principal Epidemiologist & Data Analyst
Dr. Xinning TONG, Principal Epidemiologist & Data Analyst
Dr. Xinning TONG, Principal Epidemiologist & Data Analyst
Dr. Xinning Tong earned her PhD in Public Health from the Chinese University of Hong Kong. She subsequently specialized in pharmacoepidemiology at the LKS Faculty of Medicine, University of Hong Kong, where she advanced her expertise in real-world evidence (RWE). Dr. Tong’s research spans public health epidemiology, pharmacovigilance of b
Dr. Xinning Tong earned her PhD in Public Health from the Chinese University of Hong Kong. She subsequently specialized in pharmacoepidemiology at the LKS Faculty of Medicine, University of Hong Kong, where she advanced her expertise in real-world evidence (RWE). Dr. Tong’s research spans public health epidemiology, pharmacovigilance of biological medicines, and the development of advanced clinical predictive models. Her work has been published in leading peer-reviewed journals, including Gut, Annals of the Rheumatic Diseases, International Journal of Epidemiology, and Journal of Internal Medicine.